197151-68-1Relevant articles and documents
Folic acid conjugates of a bleomycin mimic for selective targeting of folate receptor positive cancer cells
Geersing, Arjan,de Vries, Reinder H.,Jansen, Gerrit,Rots, Marianne G.,Roelfes, Gerard
, p. 1922 - 1927 (2019)
A major challenge in the application of cytotoxic anti-cancer drugs is their general lack of selectivity, which often leads to systematic toxicity due to their inability to discriminate between malignant and healthy cells. A particularly promising target for selective targeting are the folate receptors (FR) that are often over-expressed on cancer cells. Here, we report on a conjugate of the pentadentate nitrogen ligand N4Py to folic acid, via a cleavable disulphide linker, which shows selective cytotoxicity against folate receptor expressing cancer cells.
Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids
Sodji, Quaovi H.,Kornacki, James R.,McDonald, John F.,Mrksich, Milan,Oyelere, Adegboyega K.
supporting information, p. 340 - 359 (2015/04/27)
Histone deacetylase (HDAC) inhibition has recently emerged as a novel therapeutic approach for the treatment of various pathological conditions including cancer. Currently, two HDAC inhibitors (HDACi) - Vorinostat and Romidepsin - have been approved for t
Site-specific folate conjugation to a cytotoxic protein
Smith, Bryan D.,Higgin, Joshua J.,Raines, Ronald T.
experimental part, p. 5029 - 5032 (2011/10/09)
Conjugation to folic acid is known to enhance the uptake of molecules by human cells that over-produce folate receptors. Variants of bovine pancreatic ribonuclease (RNase A) that have attenuated affinity for the endogenous ribonuclease inhibitor protein (
